MissionIR's  Instablog

Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
My blog:
MissionIR Blog
  • VistaGen Therapeutics, Inc. (VSTA) Gives Second Life To Once-Promising Drug Candidates 0 comments
    Jan 6, 2014 2:12 PM | about stocks: VTGN

    Biotechnology company VistaGen Therapeutics is putting humans first with Human Clinical Trials in a Test Tube. This human pluripotent stem cell (hPSC) technology platform has been developed to provide clinically relevant predictions of potential toxicity long before drug candidates are ever tested on humans.

    VistaGen's hPSC-based bioassay systems simulate human biology much more effectively than animal testing and other nonclinical techniques and technologies currently used in drug development. This superior approximation of human physiology enables pharmaceutical companies to better predict potential pitfalls in promising drug candidates during preclinical development - potentially saving millions of dollars and countless hours. Many times, a drug candidate that showed great promise during preclinical testing ultimately fails in human trials due to unforeseen heart or liver toxicity or metabolism issues. That quickly, a potentially lifesaving drug candidate is lost to the world. Thanks to VistaGen's pioneering efforts, however, the limitations of animal and in vitro testing have been overcome and once-promising drug candidates can potentially have a second chance to be brought successfully through clinical trials.

    Human Clinical Trials in a Test Tube provides priceless toxicology prediction screening long before human subjects ever encounter a drug. With this hPSC technology, VistaGen can not only help pharmaceutical companies enjoy greater success in their drug development efforts, but the company can also create its own diverse pipeline of new proprietary drug rescue variants, revisiting discontinued small-molecule candidates that were shelved due to adverse reactions in humans.

    VistaGen is currently developing two predictive biological assay systems: CardioSafe 3D and LiverSafe 3D. CardioSafe 3D uses mature human heart cells derived from hPSCs to screen for heart toxicity in connection with the company's drug rescue activities. LiverSafe 3D, being developed in collaboration with leading stem cell researcher Dr. Gordon Keller, will similarly offer valuable predictive screening data relating to liver toxicity and metabolism issues.

    For more information about VistaGen and its advancements, visit VistaGen.com

    MissionIR provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.missionir.com

    Stocks: VTGN
Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.